Inhibikase Therapeutics (IKT)
(Real Time Quote from BATS)
$1.73 USD
-0.07 (-3.89%)
Updated Aug 6, 2025 03:14 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Inhibikase Therapeutics, Inc. has a market cap of $133.82M, which represents its share price of $1.80 multiplied by its outstanding shares number of 74.34M. As a small-cap company, IKT's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
IKT 1.73 -0.07(-3.89%)
Will IKT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IKT
Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
IKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IKT
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
Inhibikase Therapeutics (IKT) Announces $300 Million Securities Shelf Filing | IKT Stock News
Inhibikase Therapeutics files $300M mixed securities shelf
Inhibikase Therapeutics files $300M mixed securities shelf